Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YUAN YUAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1073664660
CMS profile
963347
Location
PASADENA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$91,708.59

65 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $46,061.41 29
AstraZeneca Pharmaceuticals LP $25,972.48 21
Daiichi Sankyo Inc. $10,232.04 7
Seagen Inc. $4,679.89 2
Merck Sharp & Dohme LLC $4,419.85 3
Stemline Therapeutics Inc. $124.38 1
PFIZER INC. $115.40 1
Novartis Pharmaceuticals Corporation $103.14 1

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YUAN YUAN

NPI 1073664660 · CMS profile ID 963347

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PASADENA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073664660?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YUAN YUAN, NPI 1073664660, CMS profile ID 963347. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073664660?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). YUAN YUAN, NPI 1073664660, CMS profile ID 963347. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073664660?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
YUAN YUAN, NPI 1073664660, CMS profile ID 963347, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–65 of 65 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1073664660?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

65 matching records · $91,708.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 65 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–65 of 65.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $6,720.0003/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035835403 CMS
Gilead Sciences, Inc. $242.9703/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025495321 CMS
Gilead Sciences, Inc. $1,185.0203/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025495323 CMS
Gilead Sciences, Inc. $123.6203/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025510745 CMS
Gilead Sciences, Inc. $2,270.0002/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035505935 CMS
Gilead Sciences, Inc. $583.0702/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025495315 CMS
Gilead Sciences, Inc. $849.3602/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025495317 CMS
Gilead Sciences, Inc. $1,185.5902/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025495319 CMS
Merck Sharp & Dohme LLC $4,270.0002/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048747581 CMS
Daiichi Sankyo Inc. $2,750.0002/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006591857 CMS
Merck Sharp & Dohme LLC $25.0002/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048375639 CMS
Daiichi Sankyo Inc. $125.0002/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006591273 CMS
Merck Sharp & Dohme LLC $124.8501/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048747585 CMS
Gilead Sciences, Inc. $1,890.0001/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035505929 CMS
AstraZeneca Pharmaceuticals LP $1,350.0001/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016074099 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $64,615.09 69
PY2020 $48,834.90 38
PY2021 $63,532.60 46
PY2022 $196,385.09 125
PY2023 $91,708.59 65
PY2024 $27,137.16 26
PY2025 $17,469.47 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $381,262.05 17
PY2024 Principal investigator $594,137.78 26
PY2023 Recipient $1,400.00 1
PY2023 Principal investigator $432,122.35 25
PY2022 Recipient $9,080.00 4
PY2022 Principal investigator $1,073,794.38 21
PY2021 Recipient $2,220.00 4
PY2021 Principal investigator $1,831,076.90 22
PY2020 Recipient $729.20 1
PY2020 Principal investigator $1,814,767.93 49
PY2019 Principal investigator $2,877,864.74 80

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,529.76 12/31/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 1232925821
Principal investigator 1 Merck Sharp & Dohme LLC $4,253.54 12/31/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232926941
Principal investigator 1 Merck Sharp & Dohme LLC $153,363.92 12/31/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition with Olaparib in Advanced BRCA-mutated Breast Cancers No dispute reported 06/30/2026 1232932547
Principal investigator 1 PFIZER INC. $10,000.00 10/31/2025 Covered Recipient Teaching Hospital
HUNTINGTON HOSPITAL
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1228720959
Principal investigator 1 PFIZER INC. $10,000.00 10/31/2025 Non-covered Recipient Entity
NRG Oncology Foundation
THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB No dispute reported 06/30/2026 1228721101
Principal investigator 1 Daiichi Sankyo Inc. $11,885.23 06/18/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
U31402-308 No dispute reported 06/30/2026 1223345254
Principal investigator 1 Daiichi Sankyo Inc. $10,972.93 06/18/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
U31402-308 No dispute reported 06/30/2026 1223345256
Principal investigator 1 Daiichi Sankyo Inc. $15,905.19 06/18/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
U31402-308 No dispute reported 06/30/2026 1223345258
Principal investigator 1 Merck Sharp & Dohme LLC $3,377.38 06/16/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232926939
Principal investigator 1 Genentech, Inc. $2,600.00 06/10/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211542218
Principal investigator 1 Genentech, Inc. $2,600.00 06/03/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC No dispute reported 06/30/2026 1211542211
Principal investigator 1 Eli Lilly and Company $21.90 05/27/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187882940
Principal investigator 1 Eli Lilly and Company $4,135.00 04/01/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187872567
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,461.39 02/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY No dispute reported 06/30/2026 1185540703
Principal investigator 1 Daiichi Sankyo Inc. $98,844.56 02/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
U31402-308 No dispute reported 06/30/2026 1223345260
Principal investigator 1 Merck Sharp & Dohme LLC $35,300.30 01/30/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition with Olaparib in Advanced BRCA-mutated Breast Cancers No dispute reported 06/30/2026 1232932315
Principal investigator 1 Eli Lilly and Company $10.95 01/27/2025 Non-covered Recipient Entity
TORRANCE MEMORIAL MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187892856